Stay updated on Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical-trial page displays the completed KEYNOTE-061 study record, comparing pembrolizumab with paclitaxel for advanced gastric or gastroesophageal junction cancer. It includes study eligibility, treatment arms, outcome measures, publications, and supporting documents.SummaryDifference63%

- Check16 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedAn NIH-wide announcement about updated terminology for artificial intelligence appears above the unavailable study record.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the study details with a generic error screen. This indicates an access issue rather than a substantive content update on the page.SummaryDifference20%

Stay in the know with updates to Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.